Evercore ISI Maintained Outperform for Penumbra, Inc. (PEN) Feb 25, 2026
Evercore ISI maintained an Outperform rating on Penumbra, Inc. (PEN) on February 25, 2026 and raised its price target to $360 from $340. The move is the headline in the latest PEN analyst rating update and signals continued confidence in embolization growth. The update came with a modest short‑term market reaction of -0.22% (a -$0.73 change). Meyka AI, an AI‑powered market analysis platform, tracks this as a notable maintained rating for PEN.
PEN analyst rating: Evercore ISI maintains Outperform
Evercore ISI issued the maintained Outperform rating on February 25, 2026 and raised the price target to $360 from $340. The research note highlights embolization procedure growth as the primary driver for the higher target. The update appears in reports at TheFly and Investing.com source source.
PEN price target change and investor implications
Raising the price target to $360 signals Evercore ISI expects stronger revenue or margin momentum ahead. For investors, a higher target typically implies greater upside versus prior expectations. Maintained Outperform means analysts want exposure but expect execution to prove the thesis.
Historical analyst coverage and context for PEN analyst rating
Penumbra has drawn steady sell‑side attention from medical device analysts, with Evercore ISI among the active coverages. This maintained rating continues a pattern of periodic updates tied to procedure growth and product rollout milestones. Investors should view this change as one data point within ongoing coverage.
Market reaction and stock performance linked to the PEN analyst rating
At the time of the note the stock showed a -0.22% change equal to -$0.73, indicating limited immediate impact. Market cap stands at $13,287,089,229. Price target moves often shift sentiment more than short‑term price action, especially when the rating is maintained.
What a maintained Outperform means for PEN upgrade and risks
Maintained Outperform is a positive stance that keeps Penumbra in a preferred set of names for analysts. Investors should weigh growth drivers like embolization adoption against risks such as competition, reimbursement pressure, and execution. Use the price target as a reference, not a guarantee.
Meyka grade and how we factor PEN analyst rating into ratings
Meyka AI rates PEN with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guarantees and do not constitute financial advice.
Final Thoughts
Evercore ISI’s action on February 25, 2026 — maintaining Outperform and raising the price target to $360 — keeps Penumbra on analyst radars while signaling confidence in embolization growth. The update counts as a constructive maintained rating within the broader PEN analyst rating landscape. Investors should see this as affirmation rather than a full re‑rating. Combine the new price target with company fundamentals, competitive trends, and risk factors before adjusting allocations. Remember, Meyka AI rates PEN with a grade of B+, reflecting benchmark and sector comparisons plus analyst consensus. These grades and price targets guide analysis but are not financial advice.
FAQs
What did Evercore ISI change in the latest PEN analyst rating?
Evercore ISI maintained an Outperform rating on February 25, 2026 and raised the price target to $360 from $340. The note cited embolization growth as the reason for the higher target.
Does the PEN price target raise mean you should buy PEN now?
A higher price target signals analyst confidence, but a maintained Outperform is not a buy guarantee. Investors should compare the new $360 target to personal valuation, risk tolerance, and company fundamentals.
How did the market react to the Evercore ISI PEN analyst rating update?
The immediate market reaction was muted, with a -0.22% move equal to -$0.73 at the time of reporting. Price target changes often shift sentiment more than instant price moves.
What does Meyka AI’s B+ grade mean for PEN analyst rating readers?
Meyka AI rates PEN with a grade of B+ based on S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Grades supplement but do not replace investor due diligence.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.